Publications by authors named "Eram Haider McInnes"
Article Synopsis
- A systematic review was conducted to explore the relationship between clinical and biological features and the effectiveness of two diabetes treatments: SGLT2-inhibitors and GLP1-receptor agonists, focusing on outcomes like glycaemic control, cardiovascular health, and kidney function.
- Out of over 5,600 studies screened, only 101 for SGLT2-inhibitors and 75 for GLP1-receptor agonists were included, but many had methodological flaws that limited their reliability in assessing how different patients react to these treatments.
- Findings suggest that factors like lower kidney function and reduced insulin secretion could affect treatment responses, but overall evidence is weak; further well-designed studies are needed to better understand treatment diversity and enhance
Background: A precision medicine approach in type 2 diabetes requires identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy.
Methods: We performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes.